Elutia Inc.
Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation and breast reconstruction in the United States. It operates in three segments: Device Protection, Women's Health, and Cardiovascular. The company offers EluPro, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators;… Read more
Elutia Inc. (ELUT) - Net Assets
Latest net assets as of September 2025: $-43.92 Million USD
Based on the latest financial reports, Elutia Inc. (ELUT) has net assets worth $-43.92 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($29.41 Million) and total liabilities ($73.33 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-43.92 Million |
| % of Total Assets | -149.35% |
| Annual Growth Rate | N/A |
| 5-Year Change | -322.07% |
| 10-Year Change | N/A |
| Growth Volatility | 51.07 |
Elutia Inc. - Net Assets Trend (2018–2024)
This chart illustrates how Elutia Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Elutia Inc. (2018–2024)
The table below shows the annual net assets of Elutia Inc. from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-46.26 Million | -19.84% |
| 2023-12-31 | $-38.60 Million | -666.94% |
| 2022-12-31 | $-5.03 Million | -137.22% |
| 2021-12-31 | $13.52 Million | -35.09% |
| 2020-12-31 | $20.83 Million | +137.80% |
| 2019-12-31 | $-55.11 Million | -26.97% |
| 2018-12-31 | $-43.41 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Elutia Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 18459400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $35.00K | % |
| Other Components | $183.30 Million | % |
| Total Equity | $-46.26 Million | 100.00% |
Elutia Inc. Competitors by Market Cap
The table below lists competitors of Elutia Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mindax Ltd
AU:MDX
|
$26.89 Million |
|
Beam Global
NASDAQ:BEEM
|
$26.89 Million |
|
Agarwal Industrial Corporation Limited
NSE:AGARIND
|
$26.89 Million |
|
Verde Agritech Ltd.
OTCQX:VNPKF
|
$26.89 Million |
|
WESTBRIDGE RE. EN. CORP.
F:PUQ
|
$26.88 Million |
|
Marine & General Bhd
KLSE:5078
|
$26.88 Million |
|
Shanghai Guijiu Co Ltd
SHG:600696
|
$26.88 Million |
|
General de Alquiler de Maquinaria SA
MC:GAM
|
$26.87 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Elutia Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -38,600,000 to -46,260,000, a change of -7,660,000.
- Net loss of 53,949,000 reduced equity.
- Share repurchases of 1,188,000 reduced equity.
- New share issuances of 12,390,000 increased equity.
- Other factors increased equity by 35,087,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-53.95 Million | -116.62% |
| Share Repurchases | $1.19 Million | -2.57% |
| Share Issuances | $12.39 Million | +26.78% |
| Other Changes | $35.09 Million | +75.85% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Elutia Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-4.07 | $1.09 | x |
| 2019-12-31 | $-5.17 | $1.09 | x |
| 2020-12-31 | $2.04 | $1.09 | x |
| 2021-12-31 | $1.29 | $1.09 | x |
| 2022-12-31 | $-0.36 | $1.09 | x |
| 2023-12-31 | $-2.13 | $1.09 | x |
| 2024-12-31 | $-1.59 | $1.09 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Elutia Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -221.33%
- • Asset Turnover: 0.67x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-41.20%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | -29.63% | 0.82x | 0.00x | $-7.23 Million |
| 2019 | 0.00% | -27.83% | 0.96x | 0.00x | $-6.43 Million |
| 2020 | -104.77% | -51.13% | 0.52x | 3.98x | $-23.91 Million |
| 2021 | -183.66% | -52.40% | 0.71x | 4.97x | $-26.18 Million |
| 2022 | 0.00% | -137.94% | 0.35x | 0.00x | $-32.39 Million |
| 2023 | 0.00% | -152.18% | 0.57x | 0.00x | $-33.80 Million |
| 2024 | 0.00% | -221.33% | 0.67x | 0.00x | $-49.32 Million |
Industry Comparison
This section compares Elutia Inc.'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Elutia Inc. (ELUT) | $-43.92 Million | 0.00% | N/A | $26.88 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |